# Why KPV colitis studies use nanoparticles and hydrogels

Published November 16, 2026 · Updated November 16, 2026 · Data as of November 15, 2026

In mice with dextran sodium sulfate (DSS) colitis, nanoparticle KPV protected against inflammatory and histologic changes compared with DSS alone. [1] In animal studies, it matched free KPV at a 12,000-fold lower concentration. [1] PepBank's records hold 57 findings in animals and 67 laboratory findings for [KPV](https://pepbank.io/p/kpv), and no registered trials. [2] The PepBank regulatory record lists KPV as not approved for any use. [3]

## Key points

- In mice, oral KPV reduced the incidence of DSS-induced colitis and of TNBS-induced colitis. [4]
- In animal studies, KPV in nanoparticles worked about as well as free KPV at a 12,000-fold lower concentration. [1]
- In mice with ulcerative colitis, oral hyaluronic acid-coated KPV nanoparticles in a hydrogel prevented mucosa damage better than the plain nanoparticle hydrogel. [5]
- In rats with TNBS-induced colitis, the epithelial barrier of the colon recovered after KPV/SH-PGA hydrogel treatment. [6]
- PepBank's records hold no result from a study in people for KPV. [2]
- The PepBank regulatory record lists KPV as not approved for any use, as of October 30, 2026. [3]

## Where does KPV come from?

KPV is the Lys-Pro-Val tail of alpha-melanocyte-stimulating hormone (alpha-MSH), the fragment written as alpha-MSH (11-13). In febrile rabbits, this tripeptide given into the brain ventricles brought fever down in a dose-related way. [7] In those rabbits it cut fever less than alpha-MSH (8-13) and more than alpha-MSH (10-13). [7]

In febrile rabbits, lysine-proline-valine brought fever down when it was given centrally and also when it was given peripherally. [8] In the same rabbits it was less potent than the parent molecule, full-length alpha-MSH (1-13). [7, 8]

Curo, a peptide shop with the same owner as PepBank, sells KPV. [See KPV at Curo](https://curo.you/products/kpv-10mg?utm_source=pepbank&utm_medium=blog)

## What did the early colitis studies in mice find?

In mice, oral KPV reduced the incidence of dextran sodium sulfate (DSS) colitis. The same oral peptide reduced the incidence of TNBS-induced colitis in mice. [4] In mice with DSS or TNBS colitis, oral KPV lowered expression of pro-inflammatory cytokines. [4]

In mice with DSS colitis, KPV treatment led to earlier recovery and significantly stronger regain of body weight. [9] It significantly reduced inflammatory infiltrates in the colon and myeloperoxidase activity in colonic tissue in those mice. [9]

In mice with CD45RB(hi) transfer colitis, KPV treatment led to recovery and regain of body weight. It also reduced inflammatory changes in colon histology in these mice. [9] In mice with a nonfunctional melanocortin-1 receptor and DSS colitis, KPV rescued all treated animals from death. [9]

## Why do the studies put KPV into nanoparticles and hydrogels?

In mice with DSS colitis, nanoparticle KPV (NP-KPV) protected against inflammatory and histologic changes compared with DSS alone. [1] In animal studies, that nanoparticle form worked about as well as free KPV at a 12,000-fold lower concentration. [1]

In a mouse model of ulcerative colitis, hyaluronic acid-functionalized KPV nanoparticles (HA-KPV-NPs) sped up mucosal healing and eased inflammation. [5] In the same mice, oral HA-KPV-NP/hydrogel worked much better than the KPV-NP/hydrogel system. [5]

In mice with ulcerative colitis, the oral coated nanoparticles in hydrogel prevented mucosa damage better than the KPV-NP/hydrogel system. They also downregulated tumor necrosis factor alpha (TNF-alpha) more strongly in those mice. [5] In mice with DSS-induced ulcerative colitis, KPV nanoparticles without cyclosporine A also had marked therapeutic effects. [10]

Delivery forms of KPV tested in animal colitis models

| Delivery form | What the animal study reported |
| --- | --- |
| Oral peptide (in mice) | In mice, oral KPV reduced the incidence of DSS-induced colitis. [4] |
| Nanoparticles with polysaccharide hydrogel (in mice) | In mice with DSS colitis, NP-KPV protected against inflammatory and histologic changes. [1] |
| Hyaluronic acid-coated nanoparticles (in mice) | In a mouse model of ulcerative colitis, HA-KPV-NPs sped up mucosal healing. [5] |
| Rectal KPV/SH-PGA hydrogel (in rats) | In rats with TNBS-induced colitis, it attenuated the disease activity index score. [6] |
| PMSP double-network hydrogel (in rats) | In rats with TNBS-induced colitis, PMSP-KPV recovered the colonic epithelial barrier. [11] |

## What did the rat hydrogel studies show?

In rats with TNBS-induced colitis, a rectal KPV/SH-PGA hydrogel clearly attenuated body weight loss and the disease activity index score. [6] In the same rats, the hydrogel treatment prevented colon shortening. [6]

In rats with TNBS colitis, the hydrogel treatment lowered the colonic myeloperoxidase level. [6] In those rats, the epithelial barrier of the colon recovered after the treatment. [6]

In rats with TNBS-induced colitis, KPV eased colitis significantly better when the peptide was given with the PMSP hydrogel. [11] In those rats, PMSP-KPV recovered the colonic epithelial barrier and markedly increased the abundance of beneficial gut microorganisms. [11]

## What does this mean for people?

PepBank's records hold no result from a study in people for KPV. [2] As of November 15, 2026, the record shows 0 publications and 0 findings in people. [2]

The record holds 16 publications with 57 findings in animals for KPV. [2] The record also holds 18 publications with 67 laboratory findings in cells or tissue, sorted into PepBank's [evidence classes](https://pepbank.io/methods). [2] The record holds 0 publications and 0 findings from computer models. [2]

The trial registry records in PepBank hold no registered trial that tests KPV. [2] The PepBank regulatory record lists KPV as not approved for any use in all places in the record, as of October 30, 2026. [3]

KPV is in [PepBank's list of peptides](https://pepbank.io/peptides) with 28 studies that gave the peptide and 124 results from them. [2] [The KPV studies page](https://pepbank.io/p/kpv/studies) holds 0 findings in people and 57 findings in animals. [2]

## FAQ

### Has KPV been tested in people for ulcerative colitis?

PepBank's records hold no result from a study in people for KPV. [2] As of November 15, 2026, the record shows 0 publications with findings in people and no registered trial that tests the peptide. [2] The record holds 57 findings in animals and 67 laboratory findings in cells or tissue. [2]

### Is KPV an approved medicine anywhere?

The PepBank regulatory record lists KPV as not approved for any use in all places in the record, as of October 30, 2026. [3] The research record behind it is animal and laboratory work. It has 57 findings in animals and 67 laboratory findings in cells or tissue. It has no registered trials. [2]

### How does KPV get into cells of the gut?

A mouse study points to the peptide transporter PepT1. [12] In wild-type mice with AOM/DSS-induced colitis-associated cancer, KPV prevented carcinogenesis. [12] In PepT1-knockout mice, KPV did not trigger the inhibitory effect on tumorigenesis seen in wild-type mice. So in those mice the effect depended on the transporter. [12]

### What else has KPV been studied for besides the colon?

In mice with crystal-induced peritonitis, systemic KPV significantly reduced polymorphonuclear leukocyte accumulation in the peritoneal cavity. [13] KPV also had anti-inflammatory effects in mice with IL-1beta-induced peritonitis. [13] In rabbits with corneal epithelial abrasion, topical KPV significantly reduced the percent of epithelial defect remaining compared with controls. [14]

### Does KPV work through melanocortin receptors?

In mice, the MC3/4-R antagonist SHU9119 did not block the antimigratory effect of KPV. [13] Its anti-inflammatory properties also showed up in mice with a nonfunctional MC1-R. [13] In rabbits with corneal abrasion, pre-treatment with the nitric oxide synthase inhibitor L-NAME inhibited the wound healing effect of KPV. [14]

## Sources

1. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology, 2009-11-10. https://pubmed.ncbi.nlm.nih.gov/19909746/ PMID 19909746. Evidence class: animal.
2. KPV in PepBank. PepBank, 2026-11-15. https://pepbank.io/p/kpv
3. KPV: regulatory status in PepBank. PepBank, 2026-10-30. https://pepbank.io/p/kpv
4. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2007-10-17. https://pubmed.ncbi.nlm.nih.gov/18061177/ PMID 18061177. Evidence class: animal.
5. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular therapy : the journal of the American Society of Gene Therapy, 2017-01-28. https://pubmed.ncbi.nlm.nih.gov/28143741/ PMID 28143741. Evidence class: animal.
6. Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats. ACS biomaterials science & engineering, 2021-09-21. https://pubmed.ncbi.nlm.nih.gov/34547895/ PMID 34547895. Evidence class: animal.
7. Antipyretic properties of centrally administered alpha-MSH fragments in the rabbit. Peptides, 1988-11-01. https://pubmed.ncbi.nlm.nih.gov/2854626/ PMID 2854626. Evidence class: animal.
8. Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit. Peptides, 1984-07-01. https://pubmed.ncbi.nlm.nih.gov/6333677/ PMID 6333677. Evidence class: animal.
9. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory bowel diseases, 2008-03-01. https://pubmed.ncbi.nlm.nih.gov/18092346/ PMID 18092346. Evidence class: animal.
10. A PepT1 mediated medicinal nano-system for targeted delivery of cyclosporine A to alleviate acute severe ulcerative colitis. Biomaterials science, 2019-08-13. https://pubmed.ncbi.nlm.nih.gov/31408067/ PMID 31408067. Evidence class: animal.
11. A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon. Acta biomaterialia, 2022-03-01. https://pubmed.ncbi.nlm.nih.gov/35245681/ PMID 35245681. Evidence class: animal.
12. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cellular and molecular gastroenterology and hepatology, 2016-05-01. https://pubmed.ncbi.nlm.nih.gov/27458604/ PMID 27458604. Evidence class: animal.
13. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. The Journal of pharmacology and experimental therapeutics, 2003-05-15. https://pubmed.ncbi.nlm.nih.gov/12750433/ PMID 12750433. Evidence class: animal.
14. Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Experimental eye research, 2006-09-11. https://pubmed.ncbi.nlm.nih.gov/16965771/ PMID 16965771. Evidence class: animal.

How this article is made: PepBank writes its articles from the studies and records in its database. Each claim links to its source. [Read how PepBank collects and classes evidence.](https://pepbank.io/methods)

Canonical: https://pepbank.io/blog/why-kpv-colitis-studies-use-nanoparticles-and-hydrogels

This is not medical advice.
